Tirzepatide vs Semaglutide: A Comparative Study on Efficacy and Side Effects in Type 2 Diabetes
Tirzepatide Shows More Promising Results
A recent meta-analysis of randomized trials revealed that Tirzepatide, a medication for type 2 diabetes, has been associated with higher reductions in HbA1c and weight when compared to Semaglutide. Despite the promising results, both drugs were found to increase the risk of adverse gastrointestinal events, emphasizing the importance of a well-rounded consideration of the efficacy and potential side effects.
The research, led by a team from Aristotle University of Thessaloniki in Greece, suggests that Tirzepatide could emerge as a preferred option for specific patients, especially those where weight management is a priority. However, it is crucial to consider the complete safety profile of the drug, patient preferences, and cost-effectiveness in different healthcare settings before making any decisions.
Methodology and Results
The study analyzed randomized controlled trials assessing a maintenance dose of 5 mg, 10 mg, or 15 mg once-weekly Tirzepatide or 0.5 mg, 1 mg, or 2 mg once-weekly subcutaneous Semaglutide compared with placebo for at least 12 weeks. The trials were sourced from the MEDLINE and Cochrane Library databases.
The results showed that Tirzepatide 15 mg offered the highest HbA1c reduction with a 2% decrease compared to placebo. Furthermore, all three Tirzepatide doses outperformed Semaglutide in terms of body weight loss. Tirzepatide 15 mg led to a weight loss of 10.96 kg more than placebo, while high-dose Semaglutide 2 mg resulted in a weight loss of 5.24 kg more than placebo.
Adverse Gastrointestinal Events
On the flip side, Tirzepatide 15 mg was linked to the highest risks for nausea, vomiting, and diarrhea compared to placebo. Adults receiving Tirzepatide 15 mg had a greater risk for vomiting than those receiving Semaglutide 1 mg and a higher risk for vomiting and nausea than adults receiving Semaglutide 0.5 mg.
Need for Further Studies
Despite the promising results, the study’s lead researcher notes the need for more studies to assess cardiovascular and renal outcomes with Semaglutide. A long-term cardiovascular trial comparing Tirzepatide with Dulaglutide, another glucose-lowering medication, is currently underway. Additionally, there is a need for valid country-specific cost-effectiveness evaluations comparing Tirzepatide with Semaglutide and other glucose-lowering medications.
Subscribe to BNN Breaking
Sign up for our daily newsletter covering global breaking news around the world.